BR112014019277A8 - Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica - Google Patents

Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica

Info

Publication number
BR112014019277A8
BR112014019277A8 BR112014019277A BR112014019277A BR112014019277A8 BR 112014019277 A8 BR112014019277 A8 BR 112014019277A8 BR 112014019277 A BR112014019277 A BR 112014019277A BR 112014019277 A BR112014019277 A BR 112014019277A BR 112014019277 A8 BR112014019277 A8 BR 112014019277A8
Authority
BR
Brazil
Prior art keywords
stromal stem
assay
stem cell
tissues
conducting
Prior art date
Application number
BR112014019277A
Other languages
English (en)
Other versions
BR112014019277A2 (pt
Inventor
Joseph Elliman Stephen
Original Assignee
Orbsen Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbsen Therapeutics Ltd filed Critical Orbsen Therapeutics Ltd
Publication of BR112014019277A2 publication Critical patent/BR112014019277A2/pt
Publication of BR112014019277A8 publication Critical patent/BR112014019277A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

POPULAÇÕES DE CÉLULAS-TRONCO ESTROMAIS, TECIDOS, MÉTODOS DE ISOLAMENTO DE CÉLULAS-TRONCO ESTROMAIS, MÉTODO DE OBTENÇÃO DE TECIDO, ENSAIO E MÉTODO PARA CONDUÇÃO DE ENSAIO E COMPOSIÇÃO FARMACÊUTICA. A presente invenção refere-se a células-tronco estromais que são prospectivamente isoladas da medula óssea de ser humano e, então, expandidas formando populações clonais, cultivadas e usadas, em que o isolamento é baseado em uma expressão de um marcador de superfície celular, em que o marcador de superfície celular se liga a um anticorpo e em que o dito anticorpo reage de modo cruzado com um marcador de superfície celular encontrado em células-tronco estromais de camundongo ou células-tronco estromais de rato e, opcionalmente, também em uma célula de pelo menos uma outra espécie de mamífero selecionada dentre células de camundongo, rato, cavalo, coelho e porco. As populações de células-tronco estromais úteis são positivas para SDC2.
BR112014019277A 2012-02-10 2013-02-11 Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica BR112014019277A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1202319.8A GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells
PCT/EP2013/052692 WO2013117761A1 (en) 2012-02-10 2013-02-11 Stromal stem cells

Publications (2)

Publication Number Publication Date
BR112014019277A2 BR112014019277A2 (pt) 2017-06-20
BR112014019277A8 true BR112014019277A8 (pt) 2017-07-11

Family

ID=45929927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019277A BR112014019277A8 (pt) 2012-02-10 2013-02-11 Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica

Country Status (22)

Country Link
US (9) US11230700B2 (pt)
EP (4) EP4257203A3 (pt)
JP (1) JP5829765B2 (pt)
KR (1) KR102124837B1 (pt)
CN (1) CN104302763B (pt)
AU (1) AU2013217870B2 (pt)
BR (1) BR112014019277A8 (pt)
CA (1) CA2863821C (pt)
CY (1) CY1116365T1 (pt)
DK (1) DK2758523T3 (pt)
ES (3) ES2539186T3 (pt)
GB (1) GB201202319D0 (pt)
HR (1) HRP20150594T1 (pt)
HU (1) HUE026480T2 (pt)
IN (1) IN2014KN01777A (pt)
PL (1) PL2758523T3 (pt)
PT (1) PT2758523E (pt)
RS (1) RS54073B1 (pt)
RU (1) RU2636551C2 (pt)
SI (1) SI2758523T1 (pt)
SM (1) SMT201500147B (pt)
WO (1) WO2013117761A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CA3205855A1 (en) 2013-04-16 2014-10-23 Orbsen Therapeutics Limited Medical use of syndecan-2
US20170044497A1 (en) 2014-02-12 2017-02-16 National University Of Ireland, Galway Selection and use of stem cells
KR101690872B1 (ko) 2014-08-19 2016-12-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
US9716660B2 (en) * 2014-12-11 2017-07-25 Intel Corporation Hierarchical enforcement of service flow quotas
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016154019A1 (en) * 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
WO2017122095A1 (en) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
US20210154235A1 (en) * 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
EP3652305A2 (en) * 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
WO2022179518A1 (en) * 2021-02-25 2022-09-01 Rosas Ivan O Anti-fibrotic peptides and uses thereof
CN116334214A (zh) * 2023-04-04 2023-06-27 暨南大学附属第一医院（广州华侨医院） 一种用于急性心肌梗死和稳定性心绞痛鉴别的生物标志物的ceRNA调控网络及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012403A (en) 1911-01-23 1911-12-19 Thomas W Mcneill Smoke-indicator.
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5726058A (en) 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
AU2340397A (en) 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
ES2353061T5 (es) 2000-04-25 2014-04-07 Osiris Therapeutics, Inc. Reparación de articulaciones utilizando células madre mesenquimatosas
US7442390B2 (en) * 2000-06-05 2008-10-28 University Of South Florida Method for enhancing engraftment of cells using mesenchymal progenitor cells
WO2002087609A1 (en) 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030225018A1 (en) 2002-01-18 2003-12-04 Ekker Stephen C. Syndecans and angiogenesis
CA2490261A1 (en) 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
EP1583422B1 (en) * 2002-12-05 2016-03-30 Case Western Reserve University Cell-based therapies for ischemia
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
EP2824175B2 (en) 2004-03-22 2020-10-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
CA2971062C (en) * 2004-08-16 2019-02-26 Cellresearch Corporation Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
JP5283219B2 (ja) 2006-04-20 2013-09-04 学校法人自治医科大学 ベクター産生型腫瘍標的細胞
US20070264239A1 (en) 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
WO2008085229A2 (en) 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR100883565B1 (ko) 2007-02-14 2009-02-13 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
US9289492B2 (en) 2007-07-17 2016-03-22 The General Hospital Corporation Collecting ovarian cancer stem cells from ovarian cancer cells
KR20160003307A (ko) 2007-10-17 2016-01-08 티엑셀 Tr1 세포, 중간엽 줄기 세포 및 이들의 용도
RU2010136966A (ru) * 2008-02-04 2012-03-20 Байпар Сайенсиз, Инк. (Us) Способы диагностики и лечения заболеваний, опосредованных parp
US20090220588A1 (en) 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
WO2010065239A1 (en) 2008-12-05 2010-06-10 Wake Forest University Health Sciences Stem cells from urine and methods for using the same
KR20100106744A (ko) 2009-03-24 2010-10-04 이화여자대학교 산학협력단 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물
BRPI1013771A2 (pt) 2009-04-13 2016-04-05 Apceth Gmbh & Co Kg "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
KR101301262B1 (ko) 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
KR101622650B1 (ko) 2009-12-31 2016-06-01 엘지디스플레이 주식회사 액정 전계 렌즈 및 이를 이용한 입체 표시 장치
WO2011111787A1 (ja) 2010-03-10 2011-09-15 株式会社ツーセル 間葉系幹細胞を含む細胞製剤及びその製造方法
US20130189275A1 (en) 2010-06-03 2013-07-25 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
AU2011268139B2 (en) 2010-06-18 2014-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
KR101309910B1 (ko) 2010-08-06 2013-09-17 이화여자대학교 산학협력단 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편
KR101317507B1 (ko) 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
WO2012088225A2 (en) * 2010-12-22 2012-06-28 Tulane University Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
KR101145406B1 (ko) * 2011-07-06 2012-05-15 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
SG11201407626QA (en) 2012-05-18 2014-12-30 Agency Science Tech & Res Umbilical cord mesenchymal stem cell exosomes
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
CA3205855A1 (en) 2013-04-16 2014-10-23 Orbsen Therapeutics Limited Medical use of syndecan-2
US20160220613A1 (en) 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
US10751370B2 (en) 2013-12-13 2020-08-25 Swedish Stromabio Ab Immunomodulatory compositions
EP3656387A3 (en) 2014-08-18 2020-07-01 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2016063204A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
GB201418562D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
WO2017122095A1 (en) 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
PT3416964T (pt) 2016-02-19 2021-03-09 Phoenix Molecular Designs Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro
US20210154235A1 (en) 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
EP3652305A2 (en) 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
WO2020035741A2 (en) 2018-07-05 2020-02-20 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof
EP4017512A1 (en) 2019-08-23 2022-06-29 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use

Also Published As

Publication number Publication date
AU2013217870A1 (en) 2014-09-11
BR112014019277A2 (pt) 2017-06-20
US11884936B2 (en) 2024-01-30
EP4257203A2 (en) 2023-10-11
EP2902482A1 (en) 2015-08-05
IN2014KN01777A (pt) 2015-10-23
ES2539186T3 (es) 2015-06-26
US20150037292A1 (en) 2015-02-05
US20230323307A1 (en) 2023-10-12
WO2013117761A1 (en) 2013-08-15
DK2758523T3 (da) 2015-06-22
CA2863821A1 (en) 2013-08-15
KR20140143363A (ko) 2014-12-16
EP2758523B1 (en) 2015-03-11
US10920197B2 (en) 2021-02-16
GB201202319D0 (en) 2012-03-28
JP2015509360A (ja) 2015-03-30
US11230700B2 (en) 2022-01-25
CA2863821C (en) 2023-09-19
EP3492584B1 (en) 2023-07-19
KR102124837B1 (ko) 2020-06-22
HRP20150594T1 (hr) 2015-07-17
ES2697780T3 (es) 2019-01-28
AU2013217870B2 (en) 2018-11-08
PT2758523E (pt) 2015-07-21
US20230332106A1 (en) 2023-10-19
CY1116365T1 (el) 2017-02-08
ES2959833T3 (es) 2024-02-28
EP2902482B1 (en) 2018-09-19
RU2636551C2 (ru) 2017-11-23
JP5829765B2 (ja) 2015-12-09
EP2758523A1 (en) 2014-07-30
US10907131B2 (en) 2021-02-02
US20220090019A1 (en) 2022-03-24
RU2014136711A (ru) 2016-03-27
EP3492584A1 (en) 2019-06-05
US11952589B2 (en) 2024-04-09
SMT201500147B (it) 2015-09-07
US11142747B2 (en) 2021-10-12
CN104302763B (zh) 2017-08-29
US11926848B2 (en) 2024-03-12
US11952590B2 (en) 2024-04-09
US20220112466A1 (en) 2022-04-14
CN104302763A (zh) 2015-01-21
RS54073B1 (en) 2015-10-30
HUE026480T2 (en) 2016-06-28
US20160215265A1 (en) 2016-07-28
EP4257203A3 (en) 2024-05-15
SI2758523T1 (sl) 2015-10-30
PL2758523T3 (pl) 2015-08-31
US11434471B2 (en) 2022-09-06
US20230313142A1 (en) 2023-10-05
US20180298341A1 (en) 2018-10-18
US20200078413A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
BR112014019277A8 (pt) Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BR112013004012A2 (pt) anticorpos para o receptor de fator de crescimento epidérmico 3 (her3).
BRPI0909044B8 (pt) anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
BR112012032991A2 (pt) camundongo expressando uma imunoglobulina de cadeia leve híbrida.
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
CL2007002412A1 (es) Anticuerpo especifico para el dominio extracelular del receptor de prolactina (prlr); molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que la comprenden; metodo de produccion; composicion farmaceutica que comprende al
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BRPI0820177B8 (pt) métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
WO2014139885A3 (en) Molecular targets and inhibitors of said targets, useful in the treatment of diseases associated with epithelial mesenchymal transition
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements